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Dr Frank W. Sellke (Boston, Mass). This is a very nice study in
a series from the group looking at the potential causal effects leading
to the formation of arteriovenous connections in the lungs of patients
who have undergone this operation. I have several questions.
This was a unilateral model in which you performed the CPA on
one side and you used the opposite, or normally perfused, lung as
a control. Is that correct?The Journal of ThorDr Duncan. That is correct.
Dr Sellke. Well, there are other factors involved such that the
perfusion to the control lung might not be quite normal. Would
you consider performing another control just to verify that there
are not additional changes going on in the control lung that ordinar-
ily would not occur?
Dr Duncan. Yes, I think that is a valid point. I think that might
be an important control group, especially as we go from general
pathways to specific factors. A particular problem with this expres-
sion profile technique arises from the great number of multiple com-
parisons, although it does provide a baseline to start. But certainly
going forward, as we look at more specific gene products, I think
that is a very good point.
Dr Sellke. What do you think the actual mechanism is? Is it the
changes in shear stress or absolute pressure? Do you have any idea
what might be causing these?
Dr Duncan. It certainly appears to be a complex process, a true
multifactorial process. The direct answer to your question is prob-
ably yes, and each factor you named probably contributes. Cer-
tainly there does appear to be the presence of a hepatic-derived
inhibitor, potentially in the hepatic venous effluent, that might par-
tially control pulmonary vascular development, even in the normal
state.
We see the effect of the liver on the pulmonary vasculature in
these patients because the CPA isolates the pulmonary arteries
from direct hepatic venous perfusion. However, I think it is overly
simplistic to say that this hepatic factor is the only causative factor
involved. Certainly effects related to alterations in shear stress after
CPA might be important; we have done some preliminary work that
shows this might play a causative role as well.
Dr Sellke. Listening to your talk and reading the paper, which
you gave me quite a while ago, you only examined gene expression
at 8 months, yet in disease processes and when you alter perfusion,
you can have immediate and midterm and long%2011term effects.
Do you have any idea whether the 8-month expression examination
is reflective of the actual mechanism causing the atrioventricular
malformations?
Dr Duncan. In our original published description of the model,
we reported our attempts at a quantitative assessment of this phe-
nomenon over time. We looked at microvessel density as a quantita-
tive indicator of angiogenesis. We found that the model does give
you a fairly linear relationship for microvessel density over time.
Applying DNA microarrays over time would be interesting; how-
ever, expense involved is the main limitation.
Dr Sellke. Finally, when you are looking at the cDNA micro-
array tests, even very small changes in gene expression can be sta-
tistically significant but really have very little effect on translation
to proteins. Have you done studies looking at protein expression
to see whether the changes in gene expression really mean any-
thing?
Dr Duncan. Yes, we have; that is really where we started in this.
Our initial studies looked at protein expression by using immunohis-
tochemistry. The DNA microarrays have introduced us to a new
area. The data that we see here, particularly those suggesting that
factors related to the ECM are important, have given us new areas
to explore. We are now going back and trying to corroborate these
findings in gene expression with changes in protein expression for
the MMPs and other ECM components.acic and Cardiovascular Surgery c Volume 136, Number 2 289
